AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRoyal Marsden NHS Foundation Trust
About this trial
This study will assess the utility of radiomics and artificial intelligence approaches to new lung nodules in patients who have undergone radical treatment for a previous cancer.
Eligibility criteria
Qualifiers
Biopsy confirming previous malignancy with MDT consensus and successful cancer resolution/remission following anti-cancer treatment on interval imaging or blood assay analysis
Where biopsy was not possible/confirmed for previous malignancy, MDT consensus outcome confirming cancer (+/- calculated Herder score >80% if applicable) and decision to treat as malignancy with subsequent resolution/remission following anti-cancer treatment on interval imaging or blood assay analysis
Surgical resection
Radical radiotherapy or stereotactic beam radiotherapy
Disqualifiers
CT Imaging > 10 years old
Non-solid haematological malignancies including leukaemia
Cases of radically treated primary cancer disease with early oligometastatic recurrence treated radically
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
1,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
Royal Marsden NHS Foundation Trust
Lead sponsor
Institute of Cancer Research, United Kingdom
Collaborator
National Institute for Health Research, United Kingdom
Collaborator
Royal Brompton & Harefield NHS Foundation Trust
Collaborator
Royal Marsden Partners Cancer Alliance
Collaborator
Imperial College London
Collaborator
Oxford University Hospitals NHS Trust
Collaborator
National Heart and Lung Institute
Collaborator
Source ClinicalTrials.gov